tiprankstipranks
OncoCyte reports Q3 EPS (8c), consensus (11c)
The Fly

OncoCyte reports Q3 EPS (8c), consensus (11c)

Reports Q3 revenue $1M, consensus $1.48M. "We have maintained our momentum against our major milestones across our portfolio, leveraging our newly streamlined organization, as we announced in August. Our reimbursement efforts for our VitaGraft products are in a productive dialogue with MolDx as we get close to a final determination," said Ron Andrews, CEO of Oncocyte. "We have learned a lot about the potential utility for our VitaGraft Liver test during our Early Access Program launch and have identified a compelling opportunity from the experts we have engaged to date. We also continued to make solid progress with DetermaRx in the third quarter, delivering 51% year over year growth in sample volumes and successfully onboarding new physicians and accounts."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on OCX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles